Professor of Operations & Technology Management
PhD (Georgia Institute of Technology), BEng (National Technical University of Athens)
My research interests include business analytics and data-driven decision-making processes, technology and R&D management. I’ve worked closely on research projects with numerous executives from the biopharmaceutical industry, both in large pharmaceutical organisations and small biotech companies.
I’m a member of the Operations and Technology Management subject group at Cambridge Judge Business School, which focuses on practice-based research through partner organisations to address a wide spectrum of management challenges.
If you are interested in biotechnology, check out my recent book The Business of Biotechnology and and our Research Initiative on the biopharmaceutical industry.
News and insights
When COVID-19 travel restrictions were introduced, it sparked a trend towards remote participation in clinical assessments of new medicines’ safety and efficacy. A new study co-authored at Cambridge Judge Business School outlines a framework to assess when decentralised drug trials provide the greatest value to the system.
Drug companies pay close attention to early-stage investment and testing by rivals, but only successful demonstration of clinical proof of concept really matter, says new study co-authored at Cambridge Judge Business School.
The News and Insight section of Cambridge Judge Business School’s website seeks a broad range of topics of interest to diverse audiences. In 2022, attention was focused on articles ranging from paedophile stings to Bitcoin, and from how edible insects promote sustainability to a Ukrainian finding tranquility in Cambridge.
Financial Times | 10 March 2022
“From Breakthrough to Blockbuster”, a book co-authored by Nektarios Oraiopoulos, Associate Professor at Cambridge Judge Business School, was included in the March list of top business books of the month by the Financial Times, which says the book “tells the stories of a diverse group of startups, some of which grew into international businesses — although others failed — and outcompeted Big Pharma in bringing innovative new drugs to market. The authors explain why this happened, through a biotech ecosystem of academic research, venture capital groups, contract research organisations, capital markets and founding teams.”
From Breakthrough to Blockbuster: The Business of Biotechnology, a new book co-authored by Nektarios Oraiopoulos, Associate Professor at Cambridge Judge Business School, shows how small, inexperienced entrepreneurial companies making up the biotech industry have created more life-changing medicines than all of the large pharmaceutical companies combined.
As Oraiopoulos explains: “The driving force was to bring together the complex reality of running a biotech company with the insights offered by the academic literature.”
Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge Business School, is quoted in the article. “Businesses and their leaders can use data to understand better, in an un-biased way, how they can create value for their customers,” he says. “This process enables companies to have a more focused version of the truth rooted in data, rather than having conflicting views and counterproductive arguments regarding what is good for the company.”
Forbes India, 21 December 2020
How drug companies can increase their R&D effectiveness
Fast Company, 30 April 2020
How open-source medicine could prepare us for the next pandemic
Pharma Voice, 1 February 2020
New pipeline pathways
Manufacturing Chemist, 14 August 2018
Limits of drug repurposin